NEWS

Restoring IL-2 to its cancer immunotherapy glory

Before there was PD1, there was IL-2. Can drug developers channel the effects of this pleiotropic cytokine to take back the lead?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Nature Reviews Drug Discovery 20, 163-165 (2021)

Updates & Corrections

  • Update 23 February 2021: The lead indication for nemvaleukin alfa has been updated to solid tumours.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.

Sign up to Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing